133 related articles for article (PubMed ID: 25299229)
1. Sertoli-Leydig cell tumors: hormonal profile after dynamic test with GnRH analogue: triptorelin represents a useful tool to evaluate tumoral hyperandrogenism.
Turra J; Granzotto M; Gallea M; Faggian D; Conte L; Litta P; Vettor R; Mioni R
Gynecol Endocrinol; 2015 Jan; 31(1):18-21. PubMed ID: 25299229
[TBL] [Abstract][Full Text] [Related]
2. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
Rosenfield RL; Barnes RB; Ehrmann DA
J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
[TBL] [Abstract][Full Text] [Related]
3. [Sertoli-Leydig cell tumour (arrhenoblastoma) in a patient with polycystic ovary syndrome: clinical, ultrasonographic, hormonal and histopathological evaluation].
Puzigaća S; Prelević G; Svetenović Z; Djuricić S; Kokan Dj; Radivojević U
Srp Arh Celok Lek; 2001; 129 Suppl 1():51-5. PubMed ID: 15637992
[TBL] [Abstract][Full Text] [Related]
4. Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature.
Klotz RK; Müller-Holzner E; Fessler S; Reimer DU; Zervomanolakis I; Seeber B; Mattle V; Wildt L
Exp Clin Endocrinol Diabetes; 2010 May; 118(5):291-7. PubMed ID: 20198556
[TBL] [Abstract][Full Text] [Related]
5. Sertoli-Leydig cell tumour in a 13-year-old girl.
Böttcher B; Hinney B; Keyser J; Kühnle I; Schweyer S; Emons G
Gynecol Endocrinol; 2011 Feb; 27(2):107-9. PubMed ID: 20586549
[TBL] [Abstract][Full Text] [Related]
6. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
[TBL] [Abstract][Full Text] [Related]
7. Malignant ovarian Sertoli-Leydig cell tumor localized with selective ovarian vein sampling.
Dunne C; Havelock JC
J Minim Invasive Gynecol; 2012; 19(6):789-93. PubMed ID: 23084689
[TBL] [Abstract][Full Text] [Related]
8. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
9. [In vivo and in vitro effects of GnRH analogs on ovarian Leydig cell tumor].
Emons G; Ortmann O; Pahwa GS; Löhrs U; Wetterling T; Dilling H; Oberheuser F; Knuppen R
Geburtshilfe Frauenheilkd; 1992 Aug; 52(8):487-93. PubMed ID: 1327941
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
11. Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Ghizzoni L; Virdis R; Vottero A; Cappa M; Street ME; Zampolli M; Ibañez L; Bernasconi S
J Clin Endocrinol Metab; 1996 Feb; 81(2):601-6. PubMed ID: 8636275
[TBL] [Abstract][Full Text] [Related]
12. Sertoli-Leydig cell tumor presenting hyperestrogenism in a postmenopausal woman: a case report and review of the literature.
Guo L; Yang X; Zhu H; Qiu W; Shi X; Huang B; Duan T
Taiwan J Obstet Gynecol; 2012 Dec; 51(4):620-4. PubMed ID: 23276568
[TBL] [Abstract][Full Text] [Related]
13. Virilising ovarian tumour: a case associating a Sertoli-Leydig cell tumour and a Brenner tumour.
Persechini ML; Motton S; Leguevaque P; Donadille F; Escourrou G; Vierasu B; Hamdi S; Bennet A; Caron P
Gynecol Endocrinol; 2011 May; 27(5):345-50. PubMed ID: 20569103
[TBL] [Abstract][Full Text] [Related]
14. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis.
Manieri C; Di Bisceglie C; Fornengo R; Grosso T; Zumpano E; Calvo F; Berardengo E; Volante M; Papotti M
J Endocrinol Invest; 1998 Feb; 21(2):128-32. PubMed ID: 9585388
[TBL] [Abstract][Full Text] [Related]
15. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
16. [Endocrine profile and electron microscopic study of ovarian androblastoma].
Inoue S; Fukuda O; Koyama N; Furuki Y; Munemura M; Maeyama M; Mizumoto J; Miyayama Y
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Aug; 36(8):1155-62. PubMed ID: 6096462
[TBL] [Abstract][Full Text] [Related]
17. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
18. Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour.
Picón MJ; Lara JI; Sarasa JL; Recasens JD; Clouet R; Gonzalo MA; Rovira A
Eur J Endocrinol; 2000 Jun; 142(6):619. PubMed ID: 10822225
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
20. The hormone pattern in a case of arrhenoblastoma.
Toscano V; Adamo MV; Boscherini B; Pasquino AM; Herlitzka L; Petrangeli E; Sciarra F
Eur J Pediatr; 1981 May; 136(2):203-6. PubMed ID: 6262084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
